VolitionRx Limited logo

VolitionRx Limited (VNRX)

Market Closed
3 Jun, 20:00
AMEX AMEX
$
2. 0800
-0.24
-10.34%
$
11.12M Market Cap
- P/E Ratio
- Div Yield
471,413 Volume
-0.41 Eps
$ 2.32
Previous Close
Add Transaction
Day Range
2.07 2.345
Year Range
1.91 18.8
Want to track VNRX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

VNRX closed today lower at $2.08, a decrease of -10.34% from yesterday's close, completing a monthly decrease of -20.91% or -$0.55. Over the past 12 months, VNRX stock gained 696.93%.
VNRX is not paying dividends to its shareholders.
The last earnings report, released on May 13, 2026, exceeded the consensus estimates by 0.04%. On average, the company has surpassed earnings expectations by 0.02%, based on the last three reports.
VolitionRx Limited has completed 1 stock splits, with the recent split occurring on Apr 28, 2026.
The company's stock is traded on one exchange.

VNRX Chart

People also search for

JOB
Gee Group Inc.
$ 0.23
+2.17%
Vantage Corp
$ 0.71
-0.73%
Nuburu Inc.
$ 0.18
+6.42%
Air Industries Group Inc.
$ 3.02
+0.5%
Green Circle Decarbonize Technology Limited
$ 0.8
+9.59%
VolitionRx Limited (VNRX) Q1 2026 Earnings Call Transcript

VolitionRx Limited (VNRX) Q1 2026 Earnings Call Transcript

VolitionRx Limited (VNRX) Q1 2026 Earnings Call Transcript

Seekingalpha | 2 weeks ago
VolitionRx Limited (VNRX) Q4 2025 Earnings Call Transcript

VolitionRx Limited (VNRX) Q4 2025 Earnings Call Transcript

VolitionRx Limited (VNRX) Q4 2025 Earnings Call Transcript

Seekingalpha | 2 months ago
VolitionRx Limited (VNRX) Q3 2025 Earnings Call Transcript

VolitionRx Limited (VNRX) Q3 2025 Earnings Call Transcript

VolitionRx Limited ( VNRX ) Q3 2025 Earnings Call November 14, 2025 8:30 AM EST Company Participants Louise Batchelor Day - Group Chief Marketing & Communications Officer Cameron Reynolds - Founder, CEO, President & Director Jacob Micallef - Chief Scientific Officer Terig Hughes - CFO & Treasurer Conference Call Participants Justin Walsh - JonesTrading Institutional Services, LLC, Research Division Yi Chen - H.C. Wainwright & Co, LLC, Research Division Steven Ralston - Zacks Investment Research, Inc. Bruce Jackson - The Benchmark Company, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and thank you for standing by.

Seekingalpha | 6 months ago

VolitionRx Limited (VNRX) FAQ

What is the stock price today?

The current price is $2.0800.

On which exchange is it traded?

VolitionRx Limited is listed on AMEX.

What is its stock symbol?

The ticker symbol is VNRX.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 11.12M.

Has VolitionRx Limited ever had a stock split?

VolitionRx Limited had 1 splits and the recent split was on Apr 28, 2026.

VolitionRx Limited Profile

Professional Services Industry
Industrials Sector
Cameron Reynolds CEO
AMEX Exchange
928661206 CUSIP
US Country
85 Employees
- Last Dividend
28 Apr 2026 Last Split
25 Apr 2007 IPO Date

Overview

VolitionRx Limited is a pioneering multi-national epigenetics company focused on the advancement of blood tests designed to diagnose a variety of cancers and other diseases around the globe. With its foundations in Austin, Texas, the company has made significant strides in the healthcare industry through its innovative approach to early detection and diagnosis. Leveraging their proprietary Nucleosomics technology platform, VolitionRx is at the forefront of developing non-invasive diagnostic solutions, aiming to revolutionize how diseases, especially cancer, are detected and managed worldwide.

Products and Services

Nu.Q - This innovative product line is developed to detect cancer through blood tests, offering a non-invasive, straightforward approach to cancer diagnosis. By facilitating early detection, these tests are crucial in improving patient outcomes and optimizing treatment strategies.

Nu.Q Nets - Aimed at monitoring the immune system, Nu.Q Nets are designed to provide insights into the body's defense mechanism. This is particularly beneficial in understanding and managing autoimmune diseases, cancer progression, and the effectiveness of certain treatments by providing a detailed profile of the immune system's condition.

Nu.Q Vet - Focusing on veterinary applications, the Nu.Q Vet cancer screening test is a testament to VolitionRx's commitment to comprehensive healthcare. This product extends the benefits of early cancer detection to the animal population, offering veterinarians a valuable tool in diagnosing and treating pets and livestock effectively.

Nu.Q Capture - This solution is crafted for capturing and concentrating samples to enhance the accuracy of diagnosis. By improving the quality of the sample, Nu.Q Capture aims to facilitate a more precise and definitive diagnosis, thereby reducing uncertainties and increasing the reliability of test results.

Nu.Q Discover - Nu.Q Discover offers a solution for profiling nucleosomes, which can be pivotal in understanding various diseases at a molecular level. This product supports research and development activities, driving forward the discovery of new insights and potentially leading to breakthroughs in disease diagnosis and treatment strategies.

Contact Information

Address: 13215 Bee Cave Parkway
Phone: 646 650 1351